To further ascertain the role of these mutations in lung cancer, a transgenic mouse model was developed involving KRAS mutation and it was found that mice having these mutations are more susceptible to range of tumor types, specifically early growth of lung cancer.33 Other mutations found in patients of NSCLC include BRAF mutations which can have early occurrence in lung tumorigenesis.34 The gene discussed is KRAS; the disease is lung carcinoma.